Podcast episode 12 (in German)
DSIP – the sleep peptide fact-checked
July 4, 2026
The story begins with blood from sleeping rabbits that made other animals drowsy. From it came DSIP, a peptide that is said to gently promote deep sleep and calm the stress system. The episode tells what is fascinating about it and how old the evidence is.
What it is about
In the 1970s, the Swiss researchers Schoenenberger and Monnier electrically induced deep sleep in rabbits and isolated a small protein substance from their blood: the delta sleep-inducing peptide. It is not considered a classic sleeping pill, but a regulator meant to help the body find its own rhythm. The episode explains why deep sleep in particular decreases with age and why it matters for repair, growth hormone and the nightly cleaning of the brain. Added to this are the stress side, the difference from melatonin and the question of how a substance with a short half-life can act for longer. At the end stands a charming peptide with an old, thin body of studies.
Key points
- DSIP was discovered in the 1970s by Schoenenberger and Monnier in the blood of rabbits in which deep sleep had previously been induced electrically.
- The peptide consists of 9 building blocks and is said to specifically promote the delta phases, the deepest part of the night and the most important for physical recovery.
- A night runs in cycles of around 90 minutes; the delta phases lie mainly in the first half of the night and decrease markedly with age.
- A 1984 review by Graf and Kastin in Neuroscience and Biobehavioral Reviews described diverse effects on sleep, stress and pain with complex mechanisms.
- DSIP has a very short half-life, yet the effect is said to last longer; the episode’s explanation: it acts as a starting signal, not as a sustained active substance.
- Melatonin mainly provides the timing signal for falling asleep, DSIP targets the depth and quality of sleep; the two work on different adjusting screws.
- As a report: users describe deeper, more restful sleep without grogginess in the morning; tolerability is considered good, at most with reactions at the injection site.
Where the data stop
The body of studies is old and thin. Smaller studies in people with sleep disorders reported improvements, but large modern studies are lacking, as of July 2026. The mechanism is not clear either: that DSIP as a trigger sets off a recovery cascade is an explanation, not proof. The other effects from older research, for example on pain, temperature or cortisol, are individual findings.
DSIP is not approved as a medicine and comes from the gray market; quality is a matter of trust. The good tolerability rests on few reports. The biggest lever for deep sleep needs no injection: dark, cool rooms, fixed times, less screen time in the evening and less caffeine in the afternoon. Anyone who sleeps badly on a lasting basis should have it clarified by a doctor.
Listen (in German)
Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music
Published on July 4, 2026.
The topic in the database
- An endogenous “sleep peptide”: discovered in 1977 in the blood of sleeping rabbits, described as a gentle regulator rather than a sleeping pill. Two small double-blindDSIP
All episodes in the app (German)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-10-09.